Cellectar BioSciences Unveils Pipeline Advancements in Phospholipid Drug Conjugate Oncology Therapies

Reuters12-06

Cellectar BioSciences Unveils Pipeline Advancements in Phospholipid Drug Conjugate Oncology Therapies

Cellectar BioSciences Inc. has outlined key developments in its phospholipid drug conjugate (PDC) platform, highlighting progress in multiple oncology therapeutic programs. The company is advancing its pipeline with a focus on targeted radiotherapeutics, reporting readiness for a Phase 1b/2a study with an Auger emitting therapeutic for triple negative breast cancer and finalizing the investigational new drug $(IND)$ application for CLR 225 (actinium) in solid tumors. Preclinical data with radiotherapies using isotopes such as Lu177, Pb212, and At211 were also noted. Additionally, Cellectar is optimizing the regulatory strategy for iopofosine I 131, aiming for conditional market authorization in Europe and accelerated approval in the U.S. based on positive Phase 2b data in Waldenstrom's macroglobulinemia. The company plans to pursue further development and commercialization partnerships in the U.S. and EU, as well as collaborations to support asset development. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cellectar BioSciences Inc. published the original content used to generate this news brief on December 05, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2589843808?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-06 06:49","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2589843808","market":"nz","top_or_hot":-1,"title":"Cellectar BioSciences Unveils Pipeline Advancements in Phospholipid Drug Conjugate Oncology Therapies","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Cellectar BioSciences Unveils Pipeline Advancements in Phospholipid Drug Conjugate Oncology Therapies\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Cellectar BioSciences Inc. has outlined key developments in its phospholipid drug conjugate (PDC) platform, highlighting progress in multiple oncology therapeutic programs. The company is advancing its pipeline with a focus on targeted radiotherapeutics, reporting readiness for a Phase 1b/2a study with an Auger emitting therapeutic for triple negative breast cancer and finalizing the investigational new drug <a href=\"https://laohu8.com/S/IND\">$(IND)$</a> application for CLR 225 (actinium) in solid tumors. Preclinical data with radiotherapies using isotopes such as Lu177, Pb212, and At211 were also noted. Additionally, Cellectar is optimizing the regulatory strategy for iopofosine I 131, aiming for conditional market authorization in Europe and accelerated approval in the U.S. based on positive Phase 2b data in Waldenstrom's macroglobulinemia. The company plans to pursue further development and commercialization partnerships in the U.S. and EU, as well as collaborations to support asset development. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cellectar BioSciences Inc. published the original content used to generate this news brief on December 05, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cellectar BioSciences Unveils Pipeline Advancements in Phospholipid Drug Conjugate Oncology Therapies</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCellectar BioSciences Unveils Pipeline Advancements in Phospholipid Drug Conjugate Oncology Therapies\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-06 06:49</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Cellectar BioSciences Unveils Pipeline Advancements in Phospholipid Drug Conjugate Oncology Therapies\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Cellectar BioSciences Inc. has outlined key developments in its phospholipid drug conjugate (PDC) platform, highlighting progress in multiple oncology therapeutic programs. The company is advancing its pipeline with a focus on targeted radiotherapeutics, reporting readiness for a Phase 1b/2a study with an Auger emitting therapeutic for triple negative breast cancer and finalizing the investigational new drug <a href=\"https://laohu8.com/S/IND\">$(IND)$</a> application for CLR 225 (actinium) in solid tumors. Preclinical data with radiotherapies using isotopes such as Lu177, Pb212, and At211 were also noted. Additionally, Cellectar is optimizing the regulatory strategy for iopofosine I 131, aiming for conditional market authorization in Europe and accelerated approval in the U.S. based on positive Phase 2b data in Waldenstrom's macroglobulinemia. The company plans to pursue further development and commercialization partnerships in the U.S. and EU, as well as collaborations to support asset development. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cellectar BioSciences Inc. published the original content used to generate this news brief on December 05, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251205:nNDLZ4QTB:1","article_id":"2589843808","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2589843808","pubTimestamp":1764974976,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Cellectar BioSciences Inc. has outlined key developments in its phospholipid drug conjugate  platform, highlighting progress in multiple oncology therapeutic programs. The company is advancing its pipeline with a focus on targeted radiotherapeutics, reporting readiness for a Phase 1b/2a study with an Auger emitting therapeutic for triple negative breast cancer and finalizing the investigational new drug  application for CLR 225  in solid tumors. Preclinical data with radiotherapies using isotopes such as Lu177, Pb212, and At211 were also noted. Additionally, Cellectar is optimizing the regulatory strategy for iopofosine I 131, aiming for conditional market authorization in Europe and accelerated approval in the U.S. based on positive Phase 2b data in Waldenstrom's macroglobulinemia. The company plans to pursue further development and commercialization partnerships in the U.S. and EU, as well as collaborations to support asset development. You can access the full presentation through th","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","CLRB":"Cellectar Biosciences Inc."},"translate_title":"Cellectar BioSciences公布磷脂药物偶联物肿瘤疗法的管线进展","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CLRB":0.9},"content_text":"Cellectar BioSciences Unveils Pipeline Advancements in Phospholipid Drug Conjugate Oncology Therapies\n    \n\n        Cellectar BioSciences Inc. has outlined key developments in its phospholipid drug conjugate (PDC) platform, highlighting progress in multiple oncology therapeutic programs. The company is advancing its pipeline with a focus on targeted radiotherapeutics, reporting readiness for a Phase 1b/2a study with an Auger emitting therapeutic for triple negative breast cancer and finalizing the investigational new drug $(IND)$ application for CLR 225 (actinium) in solid tumors. Preclinical data with radiotherapies using isotopes such as Lu177, Pb212, and At211 were also noted. Additionally, Cellectar is optimizing the regulatory strategy for iopofosine I 131, aiming for conditional market authorization in Europe and accelerated approval in the U.S. based on positive Phase 2b data in Waldenstrom's macroglobulinemia. The company plans to pursue further development and commercialization partnerships in the U.S. and EU, as well as collaborations to support asset development. You can access the full presentation through the link below.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cellectar BioSciences Inc. published the original content used to generate this news brief on December 05, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2589843808","isCrawlerRequest":true}